OncoSil Medical (ASX:OSL) randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.
The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.
Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.
Shares rose nearly 17% in morning trade Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。